Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Novartis
EMD Serono
Pfizer
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
Conjupro Biotherapeutics, Inc.
GlaxoSmithKline
SystImmune Inc.
Institut Paoli-Calmettes
Orano Med LLC
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
ViroMissile, Inc.
Replimune, Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
Angiex, Inc.
Memorial Sloan Kettering Cancer Center
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
General Oncology, Inc.
SystImmune Inc.
SN BioScience
Barbara Ann Karmanos Cancer Institute
Iksuda Therapeutics Ltd.
M.D. Anderson Cancer Center
Eli Lilly and Company
University of Washington
Jacobio Pharmaceuticals Co., Ltd.
NextCure, Inc.
Shanghai Juncell Therapeutics